Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes

Kidney International

Volumn 87, Issue 4, 2015, Pages 812-819

  Pavkov, Meda E ^a   Nelson, Robert G ^b   Knowler, William C ^b   Cheng, Yiling ^a   Krolewski, Andrzej S ^c,d   Niewczas, Monika A ^c,d  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetic nephropathy; ESRD; TNF

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; CREATININE; HEMOGLOBIN A1C; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE; AMERICAN INDIAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL SYSTEM PARAMETERS; RISK FACTOR; URINARY ALBUMIN TO CREATININE RATIO; ALBUMINURIA; BLOOD; CHRONIC KIDNEY FAILURE; EPIDEMIOLOGY; ETHNOLOGY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES; URINE;

ADULT; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; UNITED STATES;

EID: 84926528922     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.330     Document Type: Article

References (48)

1. Hasegawa G, Nakano K, Sawada M et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991; 40: 1007-1012.
2. Bohle A, Wehrmann M, Bogenschutz O et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259.
3. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005; 115: 1199-1209.
4. MacEwan DJ. TNF ligands and receptors-a matter of life and death. Br J Pharmacol 2002; 135: 855-875.
5. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
6. Cheung SS, Metzger DL, Wang X et al. Tumor necrosis factor-related apoptosis-inducing ligand and CD56 expression in patients with type 1 diabetes mellitus. Pancreas 2005; 30: 105-114.
7. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/-mice. Nat Immunol 2003; 4: 255-260.
8. Choi JW, Song JS, Pai SH. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults. Ann Clin Lab Sci 2004; 34: 400-404.
9. Cartland SP, Erlich JH, Kavurma MM. TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/-mice. PLoS One 2014; 9: e92952.
10. Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab 2013; 11: 578-587.
11. Di Bartolo BA, Chan J, Bennett MR et al. TNF related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe (-/-) mice. Diabetologia 2011; 54: 3157-3167.
12. Niewczas MA, Ficociello LH, Johnson AC et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4: 62-70.
13. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515.
14. Gohda T, Niewczas MA, Ficociello LH et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524.
15. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
16. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
17. Hotamisligil GS, Arner P, Atkinson RL et al. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997; 46: 451-455.
18. Bell JH, Herrera AH, Li Y et al. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 2007; 82: 173-176.
19. Hawari FI, Rouhani FN, Cui X et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci USA 2004; 101: 1297-1302.
20. Niewczas MA, Lee JE, MiJeong K et al. Regulation of leukocyte expression and soluble from concentrations of TNFR1 and TNFR2 in type 1 diabetes (Abstract). Diabetes 2013; 62: A137.
21. Al Lamki RS, Wang J, Vandenabeele P et al. TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005; 19: 1637-1645.
22. Guo G, Morrissey J, McCracken R et al. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277: F766-F772.
23. Navarro JF, Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17: 441-450.
24. Speeckaert MM, Speeckaert R, Laute M et al. Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol 2012; 36: 261-270.
25. Navarro JF, Mora C, Maca M et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 53-61.
26. Schram MT, Chaturvedi N, Schalkwijk CG et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370-378.
27. Carlsson AC, Larsson TE, Helmersson-Karlqvist J et al. Soluble TNF receptors and kidney dysfunction in the elderly. J Am Soc Nephrol 2014; 25: 1313-1320.
28. Tonelli M, Sacks F, Pfeffer M et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
29. Upadhyay A, Larson MG, Guo CY et al. Inflammation, kidney function and albuminuria in the Framingham offspring cohort. Nephrol Dial Transplant 2011; 26: 920-926.
30. Keller C, Katz R, Cushman M et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a crosssectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008; 9: 9.
31. Al-Lamki RS, Wang J, Skepper JN et al. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81: 1503-1515.
32. Hummel M, Kurian SM, Lin S et al. Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 2009; 87: 178-188.
33. Al-Lamki RS, Sadler TJ, Wang J et al. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 2010; 177: 943-954.
34. Merkle M, Ribeiro A, Wö rnle M. TLR3-dependent regulation of cytokines in human mesangial cells: a novel role for IP-10 and TNF-a in hepatitis C-associated glomerulonephritis. Am J Physiol Renal Physiol 2011; 301: F57-F69.
35. Misaki T, Yamamoto T, Suzuki S et al. Decrease in tumor necrosis factor-a receptor associated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats. Am J Pathol 2009; 175: 74-83.
36. Aten J, Roos A, Claessen N et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11: 1426-1438.
37. Shai I, Schulze MB, Manson JE et al. A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 2005; 28: 1376-1382.
38. Nelson RG, Bennett PH, Beck GJ et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 1636-1642.
39. Weil EJ, Fufaa G, Jones LI et al. Effect of Losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013; 62: 3224-3231.
40. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: S1-S150.
41. Myers BD, Nelson RG, Tan M et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995; 47: 1781-1789.
42. Knowler WC, Bennett PH, Hamman RF et al. Diabetes incidence and prevalence in Pima Indians: A 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978; 108: 497-505.
43. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 419-448.
44. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. National Institutes of Health: Washington, DC, 1979 pp 11-17.
45. Mantel N. Chi-square tests with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 59: 690-700.
46. Rosner BA. Hypothesis Testing: Person-Time Data, in Fundamentals of Biostatistics, 6th edn Thomson-Brooks/Cole: Belmont, California, 2006 pp 777-780.
47. Pepe MS, Kerr KF, Longton G et al. Testing for improvement in prediction model performance. Stat Med 2013; 32: 1467-1482.
48. Demler OV, Pencina MJ, D'Agostino RB Sr. Misuse of DeLong test to compare AUCs for nested models. Stat Med 2012; 31: 2577-2587.